BG103807A - Антиконвулсантни изохинолил-бензамидни производни - Google Patents

Антиконвулсантни изохинолил-бензамидни производни Download PDF

Info

Publication number: BG103807A
Authority: BG; Bulgaria
Prior art keywords: alkyl; hydrogen; cycloalkyl; disorders; phenyl
Prior art date: 1997-03-18

Application number

BG103807A

Other languages

Bulgarian (bg)

English (en)

Inventor

Dr. John HARLING

Dr. Barry ORLEK

Dr. Mervyn THOMPSON

Original Assignee

Smithkline Beecham P.L.C.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-18

Filing date

1999-10-13

Publication date

2001-05-31

1997-03-18 Priority claimed from GBGB9705620.4A external-priority patent/GB9705620D0/en

1997-12-17 Priority claimed from GBGB9726660.5A external-priority patent/GB9726660D0/en

1999-10-13 Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.

2001-05-31 Publication of BG103807A publication Critical patent/BG103807A/bg

Links

239000001961 anticonvulsive agent Substances 0.000 title claims description 12
230000001773 anti-convulsant effect Effects 0.000 title description 5
229960003965 antiepileptics Drugs 0.000 title description 4
MWXSOBRDESEPGR-UHFFFAOYSA-N 2-isoquinolin-1-ylbenzamide Chemical class NC(=O)C1=CC=CC=C1C1=NC=CC2=CC=CC=C12 MWXSOBRDESEPGR-UHFFFAOYSA-N 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims abstract description 123
150000001875 compounds Chemical class 0.000 claims abstract description 103
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 54
239000001257 hydrogen Substances 0.000 claims abstract description 53
-1 phenoxy, benzyloxy, benzoyl Chemical group 0.000 claims abstract description 53
150000002431 hydrogen Chemical group 0.000 claims abstract description 28
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 23
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 19
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 16
229910052736 halogen Inorganic materials 0.000 claims abstract description 15
150000002367 halogens Chemical class 0.000 claims abstract description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 11
125000002837 carbocyclic group Chemical group 0.000 claims abstract description 10
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 9
229920006395 saturated elastomer Polymers 0.000 claims abstract description 9
125000001424 substituent group Chemical group 0.000 claims abstract description 8
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
208000035475 disorder Diseases 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
238000006243 chemical reaction Methods 0.000 claims description 19
208000004296 neuralgia Diseases 0.000 claims description 18
201000006417 multiple sclerosis Diseases 0.000 claims description 17
125000000304 alkynyl group Chemical group 0.000 claims description 16
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 16
125000003342 alkenyl group Chemical group 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 12
230000001537 neural effect Effects 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 11
230000035939 shock Effects 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
208000019901 Anxiety disease Diseases 0.000 claims description 9
206010003591 Ataxia Diseases 0.000 claims description 9
206010026749 Mania Diseases 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 9
230000036506 anxiety Effects 0.000 claims description 9
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
208000024827 Alzheimer disease Diseases 0.000 claims description 8
206010058019 Cancer Pain Diseases 0.000 claims description 8
206010008748 Chorea Diseases 0.000 claims description 8
208000019695 Migraine disease Diseases 0.000 claims description 8
206010036312 Post-traumatic epilepsy Diseases 0.000 claims description 8
208000028017 Psychotic disease Diseases 0.000 claims description 8
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 8
230000016571 aggressive behavior Effects 0.000 claims description 8
229940125681 anticonvulsant agent Drugs 0.000 claims description 8
229940049706 benzodiazepine Drugs 0.000 claims description 8
150000001557 benzodiazepines Chemical class 0.000 claims description 8
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 8
208000012601 choreatic disease Diseases 0.000 claims description 8
230000002060 circadian Effects 0.000 claims description 8
229960003920 cocaine Drugs 0.000 claims description 8
206010012601 diabetes mellitus Diseases 0.000 claims description 8
206010015037 epilepsy Diseases 0.000 claims description 8
201000003631 narcolepsy Diseases 0.000 claims description 8
208000015122 neurodegenerative disease Diseases 0.000 claims description 8
208000021722 neuropathic pain Diseases 0.000 claims description 8
229960002715 nicotine Drugs 0.000 claims description 8
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 8
208000019906 panic disease Diseases 0.000 claims description 8
201000000980 schizophrenia Diseases 0.000 claims description 8
208000019116 sleep disease Diseases 0.000 claims description 8
208000004371 toothache Diseases 0.000 claims description 8
208000030507 AIDS Diseases 0.000 claims description 7
229910004013 NO 2 Inorganic materials 0.000 claims description 7
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 7
208000009205 Tinnitus Diseases 0.000 claims description 7
208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
210000002816 gill Anatomy 0.000 claims description 7
206010022437 insomnia Diseases 0.000 claims description 7
201000010901 lateral sclerosis Diseases 0.000 claims description 7
206010027599 migraine Diseases 0.000 claims description 7
208000005264 motor neuron disease Diseases 0.000 claims description 7
230000033764 rhythmic process Effects 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 7
231100000886 tinnitus Toxicity 0.000 claims description 7
230000009529 traumatic brain injury Effects 0.000 claims description 7
208000018737 Parkinson disease Diseases 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
230000007971 neurological deficit Effects 0.000 claims description 6
201000006474 Brain Ischemia Diseases 0.000 claims description 5
206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
206010008118 cerebral infarction Diseases 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 5
210000005036 nerve Anatomy 0.000 claims description 5
206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
125000005010 perfluoroalkyl group Chemical group 0.000 claims description 3
CKVJOFALHNRRTG-UHFFFAOYSA-N 3-cyano-4-propan-2-yl-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)benzamide Chemical compound C1=C(C#N)C(C(C)C)=CC=C1C(=O)NC1=CC=C2C(C)(C)CN(C)CC2=C1 CKVJOFALHNRRTG-UHFFFAOYSA-N 0.000 claims description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
210000002161 motor neuron Anatomy 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
206010043220 Temporomandibular joint syndrome Diseases 0.000 claims 3
238000011321 prophylaxis Methods 0.000 claims 3
208000008589 Obesity Diseases 0.000 claims 2
230000036973 muscularity Effects 0.000 claims 2
235000020824 obesity Nutrition 0.000 claims 2
VLYHYDMUTKXEGI-UHFFFAOYSA-N 5-bromo-n-(1,2-dimethyl-3,4-dihydro-1h-isoquinolin-5-yl)-2,4-dimethoxybenzamide Chemical compound C1=C(Br)C(OC)=CC(OC)=C1C(=O)NC1=CC=CC2=C1CCN(C)C2C VLYHYDMUTKXEGI-UHFFFAOYSA-N 0.000 claims 1
PYPQVUDHJIZQQU-UHFFFAOYSA-N 5-chloro-4-ethoxy-2-methoxy-n-(1-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)benzamide Chemical compound C1=C(Cl)C(OCC)=CC(OC)=C1C(=O)NC1=CC=CC2=C1CCNC2C PYPQVUDHJIZQQU-UHFFFAOYSA-N 0.000 claims 1
208000015943 Coeliac disease Diseases 0.000 claims 1
208000029028 brain injury Diseases 0.000 claims 1
210000005069 ears Anatomy 0.000 claims 1
SNLMALWZNRCFBB-UHFFFAOYSA-N n-(1,2-dimethyl-3,4-dihydro-1h-isoquinolin-5-yl)-2-methoxy-4-methyl-5-(trifluoromethyl)benzamide Chemical compound COC1=CC(C)=C(C(F)(F)F)C=C1C(=O)NC1=CC=CC2=C1CCN(C)C2C SNLMALWZNRCFBB-UHFFFAOYSA-N 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
239000000203 mixture Substances 0.000 description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
239000000243 solution Substances 0.000 description 31
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 20
239000008186 active pharmaceutical agent Substances 0.000 description 20
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
239000002904 solvent Substances 0.000 description 13
229940126062 Compound A Drugs 0.000 description 12
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
229910021529 ammonia Inorganic materials 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
230000004064 dysfunction Effects 0.000 description 8
239000012044 organic layer Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000012360 testing method Methods 0.000 description 8
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
239000007788 liquid Substances 0.000 description 7
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
239000008187 granular material Substances 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
239000012453 solvate Substances 0.000 description 6
206010010904 Convulsion Diseases 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
201000009032 substance abuse Diseases 0.000 description 5
GPVDHNVGGIAOQT-UHFFFAOYSA-N 2,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 4
PBKYPTQBAQQVPT-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)benzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1C(F)(F)F PBKYPTQBAQQVPT-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
239000007818 Grignard reagent Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000011097 chromatography purification Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
239000006260 foam Substances 0.000 description 4
150000004795 grignard reagents Chemical class 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
230000002265 prevention Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
VNWUPESTVBTYJM-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)benzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1C(F)(F)F VNWUPESTVBTYJM-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
150000003857 carboxamides Chemical class 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000945 filler Substances 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000003387 muscular Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
KBUFFTQWLMDJTH-UHFFFAOYSA-N 1,2-dimethyl-1h-isoquinolin-5-amine Chemical compound C1=CC=C2C(C)N(C)C=CC2=C1N KBUFFTQWLMDJTH-UHFFFAOYSA-N 0.000 description 2
OGHSMOUGIDUPFX-UHFFFAOYSA-N 1,2-dimethyl-3,4-dihydro-1h-isoquinolin-5-amine Chemical compound C1=CC=C2C(C)N(C)CCC2=C1N OGHSMOUGIDUPFX-UHFFFAOYSA-N 0.000 description 2
WXEITGQBSNFVCV-UHFFFAOYSA-N 1-methyl-1,2,3,4-tetrahydroisoquinolin-5-amine Chemical compound C1=CC=C2C(C)NCCC2=C1N WXEITGQBSNFVCV-UHFFFAOYSA-N 0.000 description 2
VDTUSEIYUROSGJ-UHFFFAOYSA-N 1-nitroisoquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=NC=CC2=C1 VDTUSEIYUROSGJ-UHFFFAOYSA-N 0.000 description 2
JVXQHSHEHLIEPE-UHFFFAOYSA-N 2,4,4-trimethyl-7-nitroisoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C(C)(C)C(=O)N(C)C(=O)C2=C1 JVXQHSHEHLIEPE-UHFFFAOYSA-N 0.000 description 2
NVCUKQLXOGOZPZ-UHFFFAOYSA-N 2-benzyl-1-methyl-1h-isoquinolin-5-amine Chemical compound C1=CC2=C(N)C=CC=C2C(C)N1CC1=CC=CC=C1 NVCUKQLXOGOZPZ-UHFFFAOYSA-N 0.000 description 2
ICDBZRYXNCPKRM-UHFFFAOYSA-N 3,4-dihydroisoquinolin-7-amine Chemical compound C1CN=CC2=CC(N)=CC=C21 ICDBZRYXNCPKRM-UHFFFAOYSA-N 0.000 description 2
HXDRDQKKWREBNN-UHFFFAOYSA-N 3-bromo-4-ethylbenzoyl chloride Chemical compound CCC1=CC=C(C(Cl)=O)C=C1Br HXDRDQKKWREBNN-UHFFFAOYSA-N 0.000 description 2
ZQVKTHRQIXSMGY-UHFFFAOYSA-N 4-Ethylbenzoic acid Chemical compound CCC1=CC=C(C(O)=O)C=C1 ZQVKTHRQIXSMGY-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 2
WOPJFSQYDOHZMK-UHFFFAOYSA-N 5-bromo-2,4-dimethoxybenzoic acid Chemical compound COC1=CC(OC)=C(C(O)=O)C=C1Br WOPJFSQYDOHZMK-UHFFFAOYSA-N 0.000 description 2
SEAXUVVXPMQUNC-UHFFFAOYSA-N 5-bromo-2-methoxy-4-propan-2-ylbenzoic acid Chemical compound COC1=CC(C(C)C)=C(Br)C=C1C(O)=O SEAXUVVXPMQUNC-UHFFFAOYSA-N 0.000 description 2
KNXDIPJNOZPOAK-UHFFFAOYSA-N 7-amino-2,4,4-trimethylisoquinoline-1,3-dione Chemical compound NC1=CC=C2C(C)(C)C(=O)N(C)C(=O)C2=C1 KNXDIPJNOZPOAK-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
208000008457 Neurologic Manifestations Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010043994 Tonic convulsion Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
239000012043 crude product Substances 0.000 description 2
230000006735 deficit Effects 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000005457 ice water Substances 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
UXAJQOWYJGUDCQ-UHFFFAOYSA-N methyl 3-chloro-4-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(OC(C)C)C(Cl)=C1 UXAJQOWYJGUDCQ-UHFFFAOYSA-N 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
CKMXAIVXVKGGFM-UHFFFAOYSA-N p-cumic acid Chemical compound CC(C)C1=CC=C(C(O)=O)C=C1 CKMXAIVXVKGGFM-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
CUNPJFGIODEJLQ-UHFFFAOYSA-M potassium;2,2,2-trifluoroacetate Chemical compound [K+].[O-]C(=O)C(F)(F)F CUNPJFGIODEJLQ-UHFFFAOYSA-M 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000005956 quaternization reaction Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 2
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
230000000304 vasodilatating effect Effects 0.000 description 2
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
CZFQDERARONAHT-UHFFFAOYSA-N 1,1,2-trimethyl-3,4,4a,5-tetrahydroisoquinolin-7-amine hydrochloride Chemical compound Cl.C1C=C(N)C=C2C(C)(C)N(C)CCC21 CZFQDERARONAHT-UHFFFAOYSA-N 0.000 description 1
LPFWKYJBTNBYON-UHFFFAOYSA-N 1,2-dimethyl-3,4,4a,5-tetrahydro-1h-isoquinolin-7-amine Chemical compound C1C=C(N)C=C2C(C)N(C)CCC21 LPFWKYJBTNBYON-UHFFFAOYSA-N 0.000 description 1
VGWAQMUVFWPCLM-UHFFFAOYSA-M 1,2-dimethyl-3,4-dihydroisoquinolin-2-ium-7-amine;iodide Chemical compound [I-].C1=C(N)C=C2C(C)=[N+](C)CCC2=C1 VGWAQMUVFWPCLM-UHFFFAOYSA-M 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
JZZLDIIDMFCOGF-UHFFFAOYSA-N 1-methyl-3,4-dihydroisoquinoline Chemical compound C1=CC=C2C(C)=NCCC2=C1 JZZLDIIDMFCOGF-UHFFFAOYSA-N 0.000 description 1
ZLHIVVQRBMFUCD-UHFFFAOYSA-N 1-methyl-7-nitro-3,4-dihydroisoquinoline Chemical compound C1=C([N+]([O-])=O)C=C2C(C)=NCCC2=C1 ZLHIVVQRBMFUCD-UHFFFAOYSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
HMDMSALIWQEZAX-UHFFFAOYSA-N 2,4,4-trimethyl-1,3-dihydroisoquinolin-7-amine Chemical compound NC1=CC=C2C(C)(C)CN(C)CC2=C1 HMDMSALIWQEZAX-UHFFFAOYSA-N 0.000 description 1
VOYAZQCEWJGYTN-UHFFFAOYSA-N 2,4,4-trimethylisoquinoline-1,3-dione Chemical compound C1=CC=C2C(C)(C)C(=O)N(C)C(=O)C2=C1 VOYAZQCEWJGYTN-UHFFFAOYSA-N 0.000 description 1
VZQUGVCUVCVFIV-UHFFFAOYSA-N 2,4-dimethoxy-5-(trifluoromethyl)benzoic acid Chemical compound COC1=CC(OC)=C(C(F)(F)F)C=C1C(O)=O VZQUGVCUVCVFIV-UHFFFAOYSA-N 0.000 description 1
PTNIWJWNLJDPEI-UHFFFAOYSA-N 2,4-dimethoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C(OC)=C1 PTNIWJWNLJDPEI-UHFFFAOYSA-N 0.000 description 1
IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
GVPLJRLCHAVKEM-UHFFFAOYSA-M 2-benzylisoquinolin-2-ium-5-amine;bromide Chemical class [Br-].C=1C=C2C(N)=CC=CC2=C[N+]=1CC1=CC=CC=C1 GVPLJRLCHAVKEM-UHFFFAOYSA-M 0.000 description 1
HALHCELYOHCVNB-UHFFFAOYSA-N 2-methoxy-4-propan-2-ylbenzoic acid Chemical compound COC1=CC(C(C)C)=CC=C1C(O)=O HALHCELYOHCVNB-UHFFFAOYSA-N 0.000 description 1
FOQRWSAGWSGEMI-UHFFFAOYSA-N 2-methoxy-5-methylsulfonyl-4-propan-2-ylbenzoic acid Chemical compound COC1=CC(C(C)C)=C(S(C)(=O)=O)C=C1C(O)=O FOQRWSAGWSGEMI-UHFFFAOYSA-N 0.000 description 1
DUVPLQVTACQQRT-UHFFFAOYSA-M 2-methyl-3,4-dihydroisoquinolin-2-ium-7-amine;iodide Chemical compound [I-].NC1=CC=C2CC[N+](C)=CC2=C1 DUVPLQVTACQQRT-UHFFFAOYSA-M 0.000 description 1
TYIQSHOVQRRJDY-UHFFFAOYSA-M 2-methylisoquinolin-2-ium-5-amine;iodide Chemical class [I-].NC1=CC=CC2=C[N+](C)=CC=C21 TYIQSHOVQRRJDY-UHFFFAOYSA-M 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
XBGXGCOLWCMVOI-UHFFFAOYSA-N 3-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC(C(F)(F)F)=C1 XBGXGCOLWCMVOI-UHFFFAOYSA-N 0.000 description 1
DOLKPFPCQQAQRD-UHFFFAOYSA-N 3-bromo-4-ethoxy-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)benzamide Chemical compound C1=C(Br)C(OCC)=CC=C1C(=O)NC1=CC=C2C(C)(C)CN(C)CC2=C1 DOLKPFPCQQAQRD-UHFFFAOYSA-N 0.000 description 1
XCKMWULLKHQZIP-UHFFFAOYSA-N 3-bromo-4-ethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1Br XCKMWULLKHQZIP-UHFFFAOYSA-N 0.000 description 1
LQFMXKIGVFPAGJ-UHFFFAOYSA-N 3-bromo-4-ethoxybenzoyl chloride Chemical compound CCOC1=CC=C(C(Cl)=O)C=C1Br LQFMXKIGVFPAGJ-UHFFFAOYSA-N 0.000 description 1
YLAAICMOEIUKSL-UHFFFAOYSA-N 3-bromo-4-ethyl-N-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)benzamide Chemical compound C1=C(Br)C(CC)=CC=C1C(=O)NC1=CC=C2C(C)(C)CN(C)CC2=C1 YLAAICMOEIUKSL-UHFFFAOYSA-N 0.000 description 1
XUESCTMXEQFNKI-UHFFFAOYSA-N 3-bromo-4-ethylbenzoic acid Chemical compound CCC1=CC=C(C(O)=O)C=C1Br XUESCTMXEQFNKI-UHFFFAOYSA-N 0.000 description 1
BBPZABXVRBFWGD-UHFFFAOYSA-N 3-bromo-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1Br BBPZABXVRBFWGD-UHFFFAOYSA-N 0.000 description 1
LHDANYMWLNUDSJ-UHFFFAOYSA-N 3-chloro-4-propan-2-yloxy-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)benzamide Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C(=O)NC1=CC=C2C(C)(C)CN(C)CC2=C1 LHDANYMWLNUDSJ-UHFFFAOYSA-N 0.000 description 1
QXSPLPLQLJAPSM-UHFFFAOYSA-N 3-chloro-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C=C1Cl QXSPLPLQLJAPSM-UHFFFAOYSA-N 0.000 description 1
QGVOYRUAXRLTJR-UHFFFAOYSA-N 3-chloro-4-propan-2-yloxybenzoyl chloride Chemical compound CC(C)OC1=CC=C(C(Cl)=O)C=C1Cl QGVOYRUAXRLTJR-UHFFFAOYSA-N 0.000 description 1
MYIRANOGEITDFA-UHFFFAOYSA-N 3-cyano-4-propan-2-ylbenzoic acid Chemical compound CC(C)C1=CC=C(C(O)=O)C=C1C#N MYIRANOGEITDFA-UHFFFAOYSA-N 0.000 description 1
SVHCWULXFKMWCB-UHFFFAOYSA-N 3-cyano-4-propan-2-ylbenzoyl chloride Chemical compound CC(C)C1=CC=C(C(Cl)=O)C=C1C#N SVHCWULXFKMWCB-UHFFFAOYSA-N 0.000 description 1
GSSNCMDCWXJTKU-UHFFFAOYSA-N 4-ethoxy-2-methoxy-5-methylsulfonylbenzoic acid Chemical compound CCOC1=CC(OC)=C(C(O)=O)C=C1S(C)(=O)=O GSSNCMDCWXJTKU-UHFFFAOYSA-N 0.000 description 1
BZMGESHAWBPCLQ-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)-n-(1,1,2-trimethyl-3,4-dihydroisoquinolin-7-yl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C)C2(C)C)C2=C1 BZMGESHAWBPCLQ-UHFFFAOYSA-N 0.000 description 1
QHQFQDKUACTCCJ-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C2C(C)(C)CN(C)CC2=C1 QHQFQDKUACTCCJ-UHFFFAOYSA-N 0.000 description 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
ZHFIISAISQLBPR-UHFFFAOYSA-N 4-nitro-4h-isoquinoline-1,3-dione Chemical compound C1=CC=C2C([N+](=O)[O-])C(=O)NC(=O)C2=C1 ZHFIISAISQLBPR-UHFFFAOYSA-N 0.000 description 1
MZPMOUKBZJDDHI-UHFFFAOYSA-N 4-tert-butyl-n-(1,2-dimethyl-3,4-dihydro-1h-isoquinolin-5-yl)-2-methoxybenzamide Chemical compound COC1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC=CC2=C1CCN(C)C2C MZPMOUKBZJDDHI-UHFFFAOYSA-N 0.000 description 1
QGNQEODJYRGEJX-UHFFFAOYSA-N 4h-isoquinoline-1,3-dione Chemical compound C1=CC=C2C(=O)NC(=O)CC2=C1 QGNQEODJYRGEJX-UHFFFAOYSA-N 0.000 description 1
LFXBTURCKYKRPT-UHFFFAOYSA-N 5-chloro-4-ethoxy-2-methoxybenzoic acid Chemical compound CCOC1=CC(OC)=C(C(O)=O)C=C1Cl LFXBTURCKYKRPT-UHFFFAOYSA-N 0.000 description 1
ULOIKHZNIQPLOL-UHFFFAOYSA-N 5-chloro-4-ethoxy-2-methoxybenzoyl chloride Chemical compound CCOC1=CC(OC)=C(C(Cl)=O)C=C1Cl ULOIKHZNIQPLOL-UHFFFAOYSA-N 0.000 description 1
XEOSENJWQTZGQL-UHFFFAOYSA-N 5-chloro-n-(1,2-dimethyl-3,4-dihydro-1h-isoquinolin-5-yl)-2-methoxy-4-propan-2-yloxybenzamide Chemical compound COC1=CC(OC(C)C)=C(Cl)C=C1C(=O)NC1=CC=CC2=C1CCN(C)C2C XEOSENJWQTZGQL-UHFFFAOYSA-N 0.000 description 1
SYPWTKMTQACNGO-UHFFFAOYSA-N 5-chlorosulfonyl-2-methoxy-4-propan-2-ylbenzoic acid Chemical compound COC1=CC(C(C)C)=C(S(Cl)(=O)=O)C=C1C(O)=O SYPWTKMTQACNGO-UHFFFAOYSA-N 0.000 description 1
TXJSDDOEHMUXNR-UHFFFAOYSA-N 5-chlorosulfonyl-4-ethoxy-2-methoxybenzoic acid Chemical compound CCOC1=CC(OC)=C(C(O)=O)C=C1S(Cl)(=O)=O TXJSDDOEHMUXNR-UHFFFAOYSA-N 0.000 description 1
HITUXDBRMKYMGO-UHFFFAOYSA-N 5-cyano-2-methoxy-4-propan-2-ylbenzoic acid Chemical compound COC1=CC(C(C)C)=C(C#N)C=C1C(O)=O HITUXDBRMKYMGO-UHFFFAOYSA-N 0.000 description 1
GVHORNVRKMSZLA-UHFFFAOYSA-N 7-nitro-3,4-dihydroisoquinoline Chemical compound C1CN=CC2=CC([N+](=O)[O-])=CC=C21 GVHORNVRKMSZLA-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000037859 AIDS-related disorder Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010011715 Cyclitis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
208000026072 Motor neurone disease Diseases 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
YAGCIXJCAUGCGI-UHFFFAOYSA-N butoxycarbonyl butyl carbonate Chemical compound CCCCOC(=O)OC(=O)OCCCC YAGCIXJCAUGCGI-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000006378 damage Effects 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
ZJNFUIGOOWEZFL-UHFFFAOYSA-N ethyl 5-bromo-2-ethoxy-4-propan-2-ylbenzoate Chemical compound CCOC(=O)C1=CC(Br)=C(C(C)C)C=C1OCC ZJNFUIGOOWEZFL-UHFFFAOYSA-N 0.000 description 1
JQDAICQKFYESSH-UHFFFAOYSA-N ethyl 5-cyano-2-ethoxy-4-propan-2-ylbenzoate Chemical compound CCOC(=O)C1=CC(C#N)=C(C(C)C)C=C1OCC JQDAICQKFYESSH-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
YZDXFUGIDTUCDA-UHFFFAOYSA-N isoquinoline-1-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NC=CC2=C1 YZDXFUGIDTUCDA-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
ZSBIMTDWIGWJPW-UHFFFAOYSA-N methyl 3-chloro-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(Cl)=C1 ZSBIMTDWIGWJPW-UHFFFAOYSA-N 0.000 description 1
VJROGSBBDLIEMZ-UHFFFAOYSA-N methyl 5-bromo-2,4-dimethoxybenzoate Chemical compound COC(=O)C1=CC(Br)=C(OC)C=C1OC VJROGSBBDLIEMZ-UHFFFAOYSA-N 0.000 description 1
WAWAHRXONKLDPR-UHFFFAOYSA-N methyl 5-bromo-2-methoxy-4-propan-2-ylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C(C)C)C=C1OC WAWAHRXONKLDPR-UHFFFAOYSA-N 0.000 description 1
JQJJGBDRZOUEAL-UHFFFAOYSA-N methyl 5-cyano-2-methoxy-4-propan-2-ylbenzoate Chemical compound COC(=O)C1=CC(C#N)=C(C(C)C)C=C1OC JQJJGBDRZOUEAL-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000007040 multi-step synthesis reaction Methods 0.000 description 1
ZANGENJVDPXYQH-UHFFFAOYSA-N n-(1,2,3,4-tetrahydroisoquinolin-1-yl)benzamide Chemical class N1CCC2=CC=CC=C2C1NC(=O)C1=CC=CC=C1 ZANGENJVDPXYQH-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
RMHJJUOPOWPRBP-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=CC2=C1 RMHJJUOPOWPRBP-UHFFFAOYSA-N 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000010333 potassium nitrate Nutrition 0.000 description 1
239000004323 potassium nitrate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000216 proconvulsive effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000012265 solid product Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
210000001738 temporomandibular joint Anatomy 0.000 description 1
KKXRPHONDRYDRT-UHFFFAOYSA-N tert-butyl 5-amino-1-methyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=CC=C2C(C)N(C(=O)OC(C)(C)C)CCC2=C1N KKXRPHONDRYDRT-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
208000028500 tonic seizure Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Addiction (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Other In-Based Heterocyclic Compounds (AREA)

BG103807A 1997-03-18 1999-10-13 Антиконвулсантни изохинолил-бензамидни производни BG103807A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9705620.4A GB9705620D0 (en)	1997-03-18	1997-03-18	Novel compounds
GBGB9726660.5A GB9726660D0 (en)	1997-12-17	1997-12-17	Novel compounds
PCT/GB1998/000781 WO1998041507A1 (fr)	1997-03-18	1998-03-16	Derives anticonvulsivants d'isoquinolyl-benzamide

Publications (1)

Publication Number	Publication Date
BG103807A true BG103807A (bg)	2001-05-31

Family

ID=26311216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103807A BG103807A (bg)	1997-03-18	1999-10-13	Антиконвулсантни изохинолил-бензамидни производни

Country Status (26)

Country	Link
US (1)	US6277861B1 (fr)
EP (1)	EP0971897A1 (fr)
JP (1)	JP2001516357A (fr)
KR (1)	KR20000076343A (fr)
CN (1)	CN1255917A (fr)
AP (1)	AP9901635A0 (fr)
AR (1)	AR012078A1 (fr)
AU (1)	AU732162B2 (fr)
BG (1)	BG103807A (fr)
BR (1)	BR9809048A (fr)
CA (1)	CA2283682A1 (fr)
CO (1)	CO4950554A1 (fr)
DZ (1)	DZ2446A1 (fr)
EA (1)	EA199900836A1 (fr)
ID (1)	ID22730A (fr)
IL (1)	IL131958A0 (fr)
MA (1)	MA24499A1 (fr)
NO (1)	NO313753B1 (fr)
NZ (1)	NZ337579A (fr)
OA (1)	OA11390A (fr)
PE (1)	PE62199A1 (fr)
PL (1)	PL335675A1 (fr)
SK (1)	SK126799A3 (fr)
TR (1)	TR199902282T2 (fr)
TW (1)	TW509679B (fr)
WO (1)	WO1998041507A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999016752A1 (fr) *	1997-09-30	1999-04-08	Molecular Designs International, Inc.	AGONISTES DE β3-ADRENORECEPTEURS, COMPOSITIONS D'AGONISTES ET PROCEDES D'UTILISATION
GB9817424D0 (en) *	1998-08-11	1998-10-07	Smithkline Beecham Plc	Novel compounds
GB9915589D0 (en)	1999-07-02	1999-09-01	Smithkline Beecham Plc	Novel compounds
US6593341B2 (en)	2001-03-29	2003-07-15	Molecular Design International, Inc.	β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US6596734B1 (en)	2002-10-11	2003-07-22	Molecular Design International, Inc.	Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
CN109608325A (zh) *	2018-12-27	2019-04-12	先尼科化工（上海）有限公司	一种卤代苯甲酸衍生物的工业化合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
ES2036213T3 (es) *	1986-10-28	1993-05-16	Smith Kline & French Laboratories Limited	Procedimiento para preparar derivados tetrahidroisoquinolin-1-ilicos de acidos carboxilicos.
GB8807922D0 (en) *	1988-04-05	1988-05-05	Fujisawa Pharmaceutical Co	Isoquinoline compound & process for preparation thereof
US4883593A (en) *	1988-10-27	1989-11-28	Bend Research, Inc.	Ultrathin-skinned asymmetric membranes by immiscible solvents treatment
GB9112721D0 (en) *	1991-06-13	1991-07-31	Smithkline Beecham Plc	Novel treatment
EP0906283A1 (fr) *	1996-06-17	1999-04-07	Smithkline Beecham Plc	Derives substitues du benzamide et leur utilisation comme anticonvulsivants

1998
- 1998-03-07 DZ DZ980056A patent/DZ2446A1/fr active
- 1998-03-16 AU AU64127/98A patent/AU732162B2/en not_active Ceased
- 1998-03-16 CN CN98805128A patent/CN1255917A/zh active Pending
- 1998-03-16 EA EA199900836A patent/EA199900836A1/ru unknown
- 1998-03-16 IL IL13195898A patent/IL131958A0/xx unknown
- 1998-03-16 BR BR9809048-8A patent/BR9809048A/pt not_active IP Right Cessation
- 1998-03-16 PL PL98335675A patent/PL335675A1/xx unknown
- 1998-03-16 AR ARP980101173A patent/AR012078A1/es not_active Application Discontinuation
- 1998-03-16 WO PCT/GB1998/000781 patent/WO1998041507A1/fr not_active Ceased
- 1998-03-16 TR TR1999/02282T patent/TR199902282T2/xx unknown
- 1998-03-16 US US09/381,369 patent/US6277861B1/en not_active Expired - Fee Related
- 1998-03-16 MA MA25000A patent/MA24499A1/fr unknown
- 1998-03-16 CA CA002283682A patent/CA2283682A1/fr not_active Abandoned
- 1998-03-16 KR KR1019997008444A patent/KR20000076343A/ko not_active Ceased
- 1998-03-16 JP JP54024798A patent/JP2001516357A/ja not_active Withdrawn
- 1998-03-16 AP APAP/P/1999/001635A patent/AP9901635A0/en unknown
- 1998-03-16 ID IDW991041D patent/ID22730A/id unknown
- 1998-03-16 EP EP98909646A patent/EP0971897A1/fr not_active Withdrawn
- 1998-03-16 CO CO98014463A patent/CO4950554A1/es unknown
- 1998-03-16 SK SK1267-99A patent/SK126799A3/sk unknown
- 1998-03-16 NZ NZ337579A patent/NZ337579A/en unknown
- 1998-03-17 PE PE1998000190A patent/PE62199A1/es not_active Application Discontinuation
- 1998-03-20 TW TW087104134A patent/TW509679B/zh not_active IP Right Cessation
1999
- 1999-09-17 NO NO19994504A patent/NO313753B1/no not_active IP Right Cessation
- 1999-09-17 OA OA9900210A patent/OA11390A/en unknown
- 1999-10-13 BG BG103807A patent/BG103807A/bg unknown

Also Published As

Publication number	Publication date
WO1998041507A1 (fr)	1998-09-24
CN1255917A (zh)	2000-06-07
DZ2446A1 (fr)	2003-01-11
IL131958A0 (en)	2001-03-19
CO4950554A1 (es)	2000-09-01
BR9809048A (pt)	2000-08-01
NO994504L (no)	1999-09-17
NO313753B1 (no)	2002-11-25
EA199900836A1 (ru)	2000-04-24
SK126799A3 (en)	2000-05-16
MA24499A1 (fr)	1998-10-01
AP9901635A0 (en)	1999-09-30
OA11390A (en)	2004-04-14
AU732162B2 (en)	2001-04-12
ID22730A (id)	1999-12-09
TW509679B (en)	2002-11-11
NO994504D0 (no)	1999-09-17
NZ337579A (en)	2001-04-27
AU6412798A (en)	1998-10-12
PE62199A1 (es)	1999-09-10
TR199902282T2 (en)	2000-07-21
US6277861B1 (en)	2001-08-21
PL335675A1 (en)	2000-05-08
CA2283682A1 (fr)	1998-09-24
AR012078A1 (es)	2000-09-27
EP0971897A1 (fr)	2000-01-19
KR20000076343A (ko)	2000-12-26
JP2001516357A (ja)	2001-09-25

Publication	Publication Date	Title
KR100568654B1 (ko)	2006-04-07	치환된 이소퀴놀린 유도체 및 진경제로서의 그의 용도
CZ416498A3 (cs)	1999-06-16	Substituovaný benzamidový derivát a jeho použití jako antikonvulsantu
WO2000007993A1 (fr)	2000-02-17	Isoquinoleines substituees et leur utilisation en tant qu'anticonvulsifs
EP1042296B1 (fr)	2004-02-25	Derives d'isoquinoline substituee et utilisation de ces derniers comme anticonvulsifs
US6277861B1 (en)	2001-08-21	Anti-convulsant isoquinolyl-benzamide derivatives
JP2007145862A (ja)	2007-06-14	置換イソキノリン誘導体および抗痙攣剤としてのその使用
US6492378B1 (en)	2002-12-10	Substituted isoquinoline derivatives and their use as anticonvulsivants
CZ326299A3 (cs)	2000-05-17	Antikonvulsivní isochinolylbenzamidové deriváty
US20010025045A1 (en)	2001-09-27	Substituted isoquinoline derivatives and their use as anticonvulsants
CZ20002221A3 (cs)	2000-11-15	Substituované deriváty isochinolinu a jejich použití jako antikonvulziva
MXPA99008627A (en)	2000-02-02	Anti-convulsant isoquinolyl-benzamide derivatives
JP2001508402A (ja)	2001-06-26	置換ベンズアミド誘導体およびそれらの抗痙攣薬としての使用
KR20000016715A (ko)	2000-03-25	치환된 벤즈아미드 유도체 및 항경련제로서의그의 용도ㅔ
HUP0000964A2 (hu)	2000-09-28	Antikonvulzáns hatású izokinolil-benzamid-származékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények